Initial manifestations and risk factors for calcinosis in juvenile dermatomyositis: A retrospective multicenter study

Yıl: 2023 Cilt: 10 Sayı: 3 Sayfa Aralığı: 298 - 305 Metin Dili: İngilizce DOI: 10.14744/nci.2021.11129 İndeks Tarihi: 27-07-2023

Initial manifestations and risk factors for calcinosis in juvenile dermatomyositis: A retrospective multicenter study

Öz:
OBJECTIVE: This study aimed to look for the initial manifestations of juvenile dermatomyositis (JDM), give follow-up results, and search for risk factors for the development of calcinosis. METHODS: The files of children with JDM diagnosed between 2005 and 2020 were reviewed retrospectively. RESULTS: The study included 48 children, 33 girls and 15 boys. The mean age at the onset of the disease was 7.6±3.6 years. The median duration of follow-up was 35 (6–144) months. Twenty-nine patients (60.4%) had monocyclic, 7 (14.6%) patients had polycyclic, and 12 (25%) patients had chronic persistent disease course. At the time of enrollment, 35 (72.9%) patients were in remission, while 13 (27.1%) patients had active disease. Calcinosis developed in 11 patients (22.9%). Children having myalgia, livedo racemosa, skin hypopigmentation, lower alanine aminotransferase (ALT) levels, and higher physician visual analog scores at the time of diagnosis had a higher risk for calcinosis. Calcinosis was also more common in children with diagnostic delay and chronic persistent disease course. None of these parameters remained independent risk factors for calcinosis in multivariate logistic regression analysis. CONCLUSION: The rate of mortality has decreased dramatically over decades in JDM, but the rate of calcinosis has not changed proportionately. Long duration of active, untreated disease is accepted as the main risk factor for calcinosis. We have seen that calcinosis was more common in children having myalgia, livedo racemosa, skin hypopigmentation, lower ALT levels, and higher physician visual analog scores at the time of diagnosis.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Huber AM. Juvenile idiopathic inflammatory myopathies. Pediatr Clin North Am 2018;65:739–56.
  • 2. Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, et al; with the Childhood Myositis Heterogeneity Collaborative Study Group. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 2013;92:25–41.
  • 3. Meyer A, Meyer N, Schaeffer M, Gottenberg JE, Geny B, Sibilia J. Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology (Oxford) 2015;54:50–63.
  • 4. Wu JQ, Lu MP, Reed AM. Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment. World J Pediatr 2020;16:31–43.
  • 5. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403–7.
  • 6. Tsaltskan V, Aldous A, Serafi S, Yakovleva A, Sami H, Mamyrova G, et al. Long-term outcomes in Juvenile Myositis patients. Semin Arthritis Rheum 2020;50:149–55.
  • 7. Chung MP, Richardson C, Kirakossian D, Orandi AB, Saketkoo LA, Rider LG, et al; International Myositis Assessment; Clinical Studies Group (IMACS) Calcinosis Scientific Interest Group. Calcinosis biomarkers in adult and juvenile dermatomyositis. Autoimmun Rev 2020;19:102533.
  • 8. Deakin CT, Yasin SA, Simou S, Arnold KA, Tansley SL, Betteridge ZE, et al; UK Juvenile Dermatomyositis Research Group. Muscle biopsy findings in combination with myositis-specific autoantibodies aid prediction of outcomes in juvenile dermatomyositis. Arthritis Rheumatol 2016;68:2806–16.
  • 9. Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med 2016;280:24–38.
  • 10. Sozeri B, Sönmez HE, Demir F, Çakan M, Öztürk K, Özdel S, et al. Time to collaborate: objectives, design, and methodology of PeRA-Research Group. North Clin Istanb 2021;8:200–2.
  • 11. Bellutti Enders F, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis 2017;76:329–40.
  • 12. Kim S, El-Hallak M, Dedeoglu F, Zurakowski D, Fuhlbrigge RC, Sundel RP. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum 2009;60:1825– 30.
  • 13. Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000;43:541–9.
  • 14. Pilkington CA, Feldman BM, Sontichai W. Juvenile dermatomyositis and other inflammatory muscle diseases. In: Petty RE, Laxer ML, Lindsley CB, Wedderburn LR, Mellins ED, Fuhlbrigge RC, editors. Textbook of Pediatric Rheumatology. 8th ed. Philadelphia: Elsevier; 2021. p. 360–76.
  • 15. Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A, Pilkington C, et al; Pediatric Rheumatology International Trials Organisation (PRINTO). The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis 2013;72:686–93.
  • 16. Sag E, Demir S, Bilginer Y, Talim B, Haliloglu G, Topaloglu H, et al. Clinical features, muscle biopsy scores, myositis specific antibody profiles and outcome in juvenile dermatomyositis. Semin Arthritis Rheum 2020;51:95–100.
  • 17. Barut K, Aydin PO, Adrovic A, Sahin S, Kasapcopur O. Juvenile dermatomyositis: a tertiary center experience. Clin Rheumatol 2017;36:361–6.
  • 18. Guseinova D, Consolaro A, Trail L, Ferrari C, Pistorio A, Ruperto N, et al. Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. Clin Exp Rheumatol 2011;29:117–24.
  • 19. Gowdie PJ, Allen RC, Kornberg AJ, Akikusa JD. Clinical features and disease course of patients with juvenile dermatomyositis. Int J Rheum Dis 2013;16:561–7.
  • 20. Okong’o LO, Esser M, Wilmshurst J, Scott C. Characteristics and outcome of children with juvenile dermatomyositis in Cape Town: a crosssectional study. Pediatr Rheumatol Online J 2016;14:60.
  • 21. Patwardhan A, Rennebohm R, Dvorchik I, Spencer CH. Is juvenile dermatomyositis a different disease in children up to three years of age at onset than in children above three years at onset? A retrospective review of 23 years of a single center’s experience. Pediatr Rheumatol Online J 2012;10:34.
  • 22. Sato JO, Sallum AM, Ferriani VP, Marini R, Sacchetti SB, Okuda EM, et al; Rheumatology Committee of the São Paulo Pediatrics Society. A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases. Clin Exp Rheumatol 2009;27:1031–8.
  • 23. Nuño L, Joven B, Carreira P, Maldonado V, Larena C, Llorente I, et al. Multicenter registry on inflammatory myositis from the Rheumatology Society in Madrid, Spain: descriptive analysis. Reumatol Clin 2017;13:331–7.
  • 24. Al-Mayouf SM, AlMutiari N, Muzaffer M, Shehata R, Al-Wahadneh A, Abdwani R, et al. Phenotypic characteristics and outcome of juvenile dermatomyositis in Arab children. Rheumatol Int 2017;37:1513–7.
  • 25. Hoeltzel MF, Oberle EJ, Robinson AB, Agarwal A, Rider LG. The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. Curr Rheumatol Rep 2014;16:467.
  • 26. Tansley SL, Betteridge ZE, Shaddick G, Gunawardena H, Arnold K, Wedderburn LR, et al; Juvenile Dermatomyositis Research Group. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology (Oxford) 2014;53:2204–8.
  • 27. Tansley SL, Simou S, Shaddick G, Betteridge ZE, Almeida B, Gunawardena H, et al. Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort. J Autoimmun 2017;84:55–64.
  • 28. Habers GE, Huber AM, Mamyrova G, Targoff IN, O’Hanlon TP, Adams S, et al; Childhood Myositis Heterogeneity Study Group. Brief report: association of myositis autoantibodies, clinical features, and environmental exposures at illness onset with disease course in juvenile myositis. Arthritis Rheumatol 2016;68:761–8.
  • 29. Tory H, Zurakowski D, Kim S; CARRA Juvenile Dermatomyositis Quality Measures Workgroup for the CARRA Registry Investigators. Patient and physician discordance of global disease assessment in juvenile dermatomyositis: findings from the Childhood Arthritis & Rheumatology Research Alliance Legacy Registry. Pediatr Rheumatol Online J 2020;18:5.
  • 30. Huber A, Feldman BM. Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going? Curr Rheumatol Rep 2005;7:441–6.
  • 31. Varnier GC, Consolaro A, Maillard S, Pilkington C, Ravelli A. Comparison of treatments and outcomes of children with juvenile dermatomyositis followed at two European tertiary care referral centers. Rheumatology (Oxford) 2021;60:5419–23.
  • 32. Mathiesen P, Hegaard H, Herlin T, Zak M, Pedersen FK, Nielsen S. Long-term outcome in patients with juvenile dermatomyositis: a crosssectional follow-up study. Scand J Rheumatol 2012;41:50–8.
APA Çakan M, Özdel S, Karadağ Ş, ULU K, Çakmak F, otar yener g, Ozturk K, Bağlan E, Sönmez H, demir f, sozeri b, Aktay Ayaz N (2023). Initial manifestations and risk factors for calcinosis in juvenile dermatomyositis: A retrospective multicenter study. , 298 - 305. 10.14744/nci.2021.11129
Chicago Çakan Mustafa,Özdel Semanur,Karadağ Şerife Gül,ULU KADİR,Çakmak Figen,otar yener gulcin,Ozturk Kubra,Bağlan Esra,Sönmez Hafize Emine,demir ferhat,sozeri betul,Aktay Ayaz Nuray Initial manifestations and risk factors for calcinosis in juvenile dermatomyositis: A retrospective multicenter study. (2023): 298 - 305. 10.14744/nci.2021.11129
MLA Çakan Mustafa,Özdel Semanur,Karadağ Şerife Gül,ULU KADİR,Çakmak Figen,otar yener gulcin,Ozturk Kubra,Bağlan Esra,Sönmez Hafize Emine,demir ferhat,sozeri betul,Aktay Ayaz Nuray Initial manifestations and risk factors for calcinosis in juvenile dermatomyositis: A retrospective multicenter study. , 2023, ss.298 - 305. 10.14744/nci.2021.11129
AMA Çakan M,Özdel S,Karadağ Ş,ULU K,Çakmak F,otar yener g,Ozturk K,Bağlan E,Sönmez H,demir f,sozeri b,Aktay Ayaz N Initial manifestations and risk factors for calcinosis in juvenile dermatomyositis: A retrospective multicenter study. . 2023; 298 - 305. 10.14744/nci.2021.11129
Vancouver Çakan M,Özdel S,Karadağ Ş,ULU K,Çakmak F,otar yener g,Ozturk K,Bağlan E,Sönmez H,demir f,sozeri b,Aktay Ayaz N Initial manifestations and risk factors for calcinosis in juvenile dermatomyositis: A retrospective multicenter study. . 2023; 298 - 305. 10.14744/nci.2021.11129
IEEE Çakan M,Özdel S,Karadağ Ş,ULU K,Çakmak F,otar yener g,Ozturk K,Bağlan E,Sönmez H,demir f,sozeri b,Aktay Ayaz N "Initial manifestations and risk factors for calcinosis in juvenile dermatomyositis: A retrospective multicenter study." , ss.298 - 305, 2023. 10.14744/nci.2021.11129
ISNAD Çakan, Mustafa vd. "Initial manifestations and risk factors for calcinosis in juvenile dermatomyositis: A retrospective multicenter study". (2023), 298-305. https://doi.org/10.14744/nci.2021.11129
APA Çakan M, Özdel S, Karadağ Ş, ULU K, Çakmak F, otar yener g, Ozturk K, Bağlan E, Sönmez H, demir f, sozeri b, Aktay Ayaz N (2023). Initial manifestations and risk factors for calcinosis in juvenile dermatomyositis: A retrospective multicenter study. İstanbul Kuzey Klinikleri, 10(3), 298 - 305. 10.14744/nci.2021.11129
Chicago Çakan Mustafa,Özdel Semanur,Karadağ Şerife Gül,ULU KADİR,Çakmak Figen,otar yener gulcin,Ozturk Kubra,Bağlan Esra,Sönmez Hafize Emine,demir ferhat,sozeri betul,Aktay Ayaz Nuray Initial manifestations and risk factors for calcinosis in juvenile dermatomyositis: A retrospective multicenter study. İstanbul Kuzey Klinikleri 10, no.3 (2023): 298 - 305. 10.14744/nci.2021.11129
MLA Çakan Mustafa,Özdel Semanur,Karadağ Şerife Gül,ULU KADİR,Çakmak Figen,otar yener gulcin,Ozturk Kubra,Bağlan Esra,Sönmez Hafize Emine,demir ferhat,sozeri betul,Aktay Ayaz Nuray Initial manifestations and risk factors for calcinosis in juvenile dermatomyositis: A retrospective multicenter study. İstanbul Kuzey Klinikleri, vol.10, no.3, 2023, ss.298 - 305. 10.14744/nci.2021.11129
AMA Çakan M,Özdel S,Karadağ Ş,ULU K,Çakmak F,otar yener g,Ozturk K,Bağlan E,Sönmez H,demir f,sozeri b,Aktay Ayaz N Initial manifestations and risk factors for calcinosis in juvenile dermatomyositis: A retrospective multicenter study. İstanbul Kuzey Klinikleri. 2023; 10(3): 298 - 305. 10.14744/nci.2021.11129
Vancouver Çakan M,Özdel S,Karadağ Ş,ULU K,Çakmak F,otar yener g,Ozturk K,Bağlan E,Sönmez H,demir f,sozeri b,Aktay Ayaz N Initial manifestations and risk factors for calcinosis in juvenile dermatomyositis: A retrospective multicenter study. İstanbul Kuzey Klinikleri. 2023; 10(3): 298 - 305. 10.14744/nci.2021.11129
IEEE Çakan M,Özdel S,Karadağ Ş,ULU K,Çakmak F,otar yener g,Ozturk K,Bağlan E,Sönmez H,demir f,sozeri b,Aktay Ayaz N "Initial manifestations and risk factors for calcinosis in juvenile dermatomyositis: A retrospective multicenter study." İstanbul Kuzey Klinikleri, 10, ss.298 - 305, 2023. 10.14744/nci.2021.11129
ISNAD Çakan, Mustafa vd. "Initial manifestations and risk factors for calcinosis in juvenile dermatomyositis: A retrospective multicenter study". İstanbul Kuzey Klinikleri 10/3 (2023), 298-305. https://doi.org/10.14744/nci.2021.11129